BiotechTube
Home/Pipeline/QELBREE (viloxazine ER)

QELBREE (viloxazine ER)

ADHD

ApprovedCommercial

Key Facts

Indication
ADHD
Phase
Approved
Status
Commercial
Company
Supernus Pharmaceuticals

About Supernus Pharmaceuticals

Supernus Pharmaceuticals is a publicly traded CNS-focused biopharmaceutical company with a mission to improve patient lives through innovative neurology and psychiatry treatments. The company has successfully built a commercial foundation with eight marketed products and is advancing a pipeline featuring late-stage candidates for treatment-resistant depression and severe epilepsy. Its strategy combines internal R&D powered by proprietary drug delivery platforms with strategic acquisitions, such as Sage Therapeutics, to solidify its position as a comprehensive CNS therapeutics leader.

View full company profile

Therapeutic Areas

NeurologyPsychiatry

Other ADHD Drugs

DrugCompanyPhase
Undisclosed ProgramCuremarkPreclinical
NRCT-101SRNeurocentriaPhase 2b/3
XELSTRYMNoven PharmaceuticalsApproved
DAYTRANANoven PharmaceuticalsApproved
JORNAY PMCollegium PharmaceuticalMarketed
AZSTARYSCollegium PharmaceuticalAcquisition Pending
CTx-1301CingulatePhase 3
CTx-1302CingulatePhase 3